News & Events
September 17, 2019
C-Path and NORD Rare Disease Cures Accelerator Data and Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD
C-Path and the National Organization for Rare Disorders® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases.
July 14, 2019 - July 18, 2019
Poster Presentation at the 2019 Alzheimer’s Association International Conference, July 14-18, 2019, Los Angeles, CA
The Alzheimer’s Association International Conference (AAIC) is an important annual scientific meeting where international investigators, clinicians and care providers gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science. This year’s conference will be hosted in Los Angeles, CA, between July 14th and 18th.
Each year, on behalf of our consortium members, CPAD attends AAIC to share the consortium’s vision, goals, and latest milestones of our work with the research community, to educate ourselves on latest developments and trends, and to meet and exchange information with our members and other key opinion leaders. This year, one poster (P4-253) was accepted for presentation.
May 16, 2019
Best Practices for Avoiding Paper Backup When Implementing Electronic Approaches to Patient-Reported Outcome Data Collection in Clinical Trials (May 16, 2019)This webinar provides an overview of the issues related to the use of paper backups in studies for which PRO data is collected electronically. Viable strategies to eliminate the necessity of a paper-backup system are provided. Presenters: Cindy Howry, MS (.assisTek) and Paul O’Donohoe, MSc (Medidata Solutions) PDF version...
- May 16, 2019
May 1, 2019 - May 3, 2019
2019 Annual INC Neonatal Scientific WorkshopMay 1-3, 2019 Hyatt Regency Bethesda, Maryland Meeting Objectives: Share regulatory perspectives on developing safe and effective therapies for neonates. Provide foundational knowledge on innovative, regulated medicines development and factors influencing Go/No-Go decisions throughout the development pipeline. Discuss endpoints for clinical trials to evaluate pain medications. Address neonatal opioid issues through optimizing trial design for......